Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer

NCT05508126 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Phase

Observational

Started

2021-11-01

Last updated

2024-10-15

Condition(s) studied

Gastric Cancer Stage

Investigational drug(s) / intervention(s)

DECT examinationmpMRI examination

DECT examination: DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).

mpMRI examination: The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).

Study summary

Accurate preoperative staging of gastric cancer is of major importance for guiding therapeutic decision-making, preventing both under- and over-treatment. The purpose of this study is to investigate the diagnostic performance of the Multi-parametric magnetic resonance imaging (mpMRI) and dual-energy computed tomography (DECT) in gastric cancer.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Consecutive patients with preoperative pathologically confirmed GC by endoscopy and preoperative imaging data (DECT/mpMRI) were included. * No contraindications for CT/MRI examination * Written informed consent Exclusion Criteria: * Patients with a history of previous therapy. * Patients with recurrent gastric cancer * Patients with a history of severe allergy to contrast agents * Patients with imaging artefacts affect the evaluation

Primary outcome measure(s)

Diagnostic performance of DECT and mpMRI in tumor staging assessment — 2 years
Accuracy for both imaging techniques in the prediction of tumor staging.
Diagnostic performance of DECT and mpMRI in tumor restaging assessment — 2 years
Accuracy for both imaging techniques in the prediction of tumor restaging.

Trial sites (1)

Facility	City	Region	Status
Yu-Dong Zhang	Nanjing	China	Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS) Recruiting

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib Recruiting

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 Recruiting

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer Starting soon

Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma Recruiting

Other trials for the same condition

Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy Recruiting

AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT Recruiting

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05508126 on ClinicalTrials.gov ↗ ← All trials in China